SRSF2 and myelodysplastic syndrome: Clinical features of patients with isolated +8 and the presence of mutations in STAG2, SRSF2 or RUNX1 differed from MDS patients without +8 classified as high/very high risk by the IPSS-R in levels of hemoglobin and percentage of BM blasts (Table S5).